15 recruiting, 7 completed, 7 not yet recruiting, 1 active not recruiting. 22 Phase 2, 6 Phase 1, 6 Phase 3.
Follow zanidatamab: new trials by email Literature Review of zanidatamab trials Research Report on zanidatamab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer Futibatinib, Ivosidenib + Capecitabine, Zanidatamab + Capecitabine - Biliary Tract Cancer (BTC) | Phase 3 | Not yet recruiting | UNICANCER | 990 | 2027-01-02 | 2026-08-04 |
| Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract Tumors Zanidatamab - Biliary Tract Cancer | Phase 2 | Not yet recruiting | Anhui Provincial Hospital | 15 | 2026-11-30 | 2026-10-01 |
| Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA Zanidatamab - Esophageal Cancer, GastroEsophageal Cancer | Not yet recruiting | Jazz Pharmaceuticals | 300 | 2026-10-01 | 2026-10-02 | |
| AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas Tislelizumab, Leucovorin, Oxaliplatin - Gastroesophageal Adenocarcinoma | Phase 2 | Recruiting | American Association for Cancer Research | 242 | 2026-07-20 | 2026-10-05 |
| Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer Zanidatamab, Tucatinib, Capecitabine - HER 2 Positive Advanced Breast Cancer, Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | MedSIR | 24 | 2026-07-01 | 2026-04-23 |
| Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study Zanidatamab, Oxaliplatin, Capecitabine - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Zhifeng Zhao, PhD | 46 | 2026-07-01 | 2026-07-06 |
| An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy Zanidatamab - Neoplasms, Solid Tumors | Phase 2 | Not yet recruiting | Haihua Yuan | 10 | 2026-06-15 | 2026-06-08 |
| Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment Zanidatamab, Resection, Patient Observation - Colon Carcinoma, Colorectal Carcinoma | Phase 2 | Recruiting | Emory University | 38 | 2026-04-07 | 2026-04-17 |
| Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients Zanidatamab, Pembrolizumab, mFOLFOX - Gastroesophageal Adenocarcinoma, First Line Therapy | Phase 2 | Recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 80 | 2026-01-16 | 2026-06-30 |
| Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET) short-course radiotherapy, Zanidatamab, Tisleizumab(BGB-A317) - Locally Advanced Rectal Cancer (LARC), Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Tao Zhang | 70 | 2026-01-15 | 2025-11-24 |
| Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene. Zanidatamab - Non-Small Cell Lung Cancer, Sarcoma | Phase 2 | Recruiting | UNICANCER | 105 | 2025-10-30 | 2025-12-19 |
| Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC Zanidatamab, Tislelizumab, Cisplatin - Muscle Invasive Bladder Cancer (MIBC) | Phase 2 | Recruiting | Fujian Medical University Union Hospital | 25 | 2025-10-25 | 2025-12-22 |
| A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer Zanidatamab, Paclitaxel, Docetaxel - HER2-positive Breast Cancer, Breast Cancer | Phase 2 | Recruiting | Jazz Pharmaceuticals | 125 | 2025-09-24 | 2026-10-01 |
| A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors Zanidatamab - Breast Cancer, Gastric Cancer | Phase 2 | Recruiting | Jazz Pharmaceuticals | 200 | 2025-01-14 | 2026-07-10 |
| A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Zanidatamab, Trastuzumab, Eribulin - Metastatic HER2-positive Breast Cancer | Phase 3 | Recruiting | Jazz Pharmaceuticals | 550 | 2024-08-13 | 2026-02-10 |
| Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer Zanidatamab, Cisplatin, Gemcitabine - Biliary Tract Cancer | Phase 3 | Recruiting | Jazz Pharmaceuticals | 286 | 2024-07-19 | 2026-09-14 |
| Personalized Medicine for Advanced Biliary Cancer Patients Futibatinib, Ivosidenib, Zanidatamab - Biliary Tract Neoplasms | Phase 3 | Recruiting | UNICANCER | 800 | 2024-07-18 | 2026-05-19 |
| Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread Zongertinib, Trastuzumab deruxtecan, Trastuzumab emtansine - Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Boehringer Ingelheim | 768 | 2024-06-28 | 2026-10-14 |
| Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma Paclitaxel, Ramucirumab, Zanidatamab - Gastroesophageal Adenocarcinoma | Phase 2 | Recruiting | Canadian Cancer Trials Group | 168 | 2024-04-16 | 2026-08-11 |
| PRE-ISPY Phase I/II Oncology Platform Program ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab - HER2-positive Breast Cancer, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 280 | 2023-02-15 | 2026-09-30 |
Showing 20 of 31. Sign in to see all of them.
Breast Neoplasms (10) · Colorectal Neoplasms (8) · Stomach Neoplasms (8) · Biliary Tract Neoplasms (6) · Esophageal Neoplasms (4) · Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Cholangiocarcinoma (3) · Ovarian Neoplasms (3) · Adenocarcinoma Of Esophagus (2) · Carcinoma, Transitional Cell (2) · Colonic Neoplasms (2) · Endometrial Neoplasms (2) · Gallbladder Neoplasms (2) · Head and Neck Neoplasms (2)
Jazz Pharmaceuticals (12) · UNICANCER (3) · QuantumLeap Healthcare Collaborative (2) · American Association for Cancer Research (1) · Anhui Provincial Hospital (1) · BeOne Medicines (1) · BeiGene (1) · Boehringer Ingelheim (1) · Canadian Cancer Trials Group (1) · Emory University (1) · Fujian Medical University Union Hospital (1) · Haihua Yuan (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · M.D. Anderson Cancer Center (1) · MedSIR (1)
United States (18) · South Korea (10) · Canada (9) · France (9) · Spain (9) · China (8) · Italy (8) · United Kingdom (7) · Germany (6) · Belgium (5) · Japan (5) · Chile (4) · Taiwan (4) · Australia (3) · Brazil (3)
Julien Edeline, MD (2) · Alexander Stein, Prof. Dr. (1) · Elena Elimova (1) · Ivan Borbath, MD (1) · Jianjun Yang, Prof. (1) · John Bridgewater, MD (1) · Juan W Valle (1) · Laura Esserman, MD, MBA (1) · Malka David, MD (1) · Olumide B. Gbolahan, MBBS, MSc (1) · Paula R Pohlmann, MD, MSc, PhD (1) · Phillip Garfin, MD, PhD (1) · Salah-Eddin Al-Batran, Prof. Dr. (1)
PMID 41324998, PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 27406346, PMID 27406347, PMID 28851423, PMID 32031889, PMID 32053137, PMID 32450725, PMID 32701140, PMID 34529000, PMID 34741021, PMID 35623341, PMID 35993306, PMID 36000541, PMID 36069821, PMID 36400106, PMID 36456573, PMID 37029329, PMID 37276871, PMID 37325931, PMID 37505107, PMID 38086377, PMID 38180338, PMID 38745646, PMID 39114870, PMID 39158353, PMID 39277671, PMID 39277672, PMID 39613746, PMID 39625569, PMID 40339592, PMID 40341124, PMID 40473445, PMID 40526879, PMID 40551254, PMID 40639409, PMID 40679371, PMID 40777112, PMID 41108088, PMID 41202501, PMID 41879562, PMID 42202319, PMID 42530945, PMID 42545411, PMID 42619946, PMID 42773107, PMID 42811224
2025 (5), 2023 (4), 2019 (2), P30CA138292 (1)